yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Today's Top SOA Links

World Multiple Myeloma Drug Treatment Market 2012-2022

NEW YORK, Nov. 8, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

World Multiple Myeloma Drug Treatment Market 2012-2022

Report Details
Your guide to trends and revenue prospects for treating multiple myeloma

See what the future holds for products to treat multiple myeloma. Visiongain's updated report gives you revenue predictions to 2022. There you find data, trends, opportunities and commercial prospects.

Our study lets you assess forecasted sales at overall world market, product and national level. Those analyses help you see the future of that industry and market. 

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, news, research and development (R&D) and business outlooks. You receive 42 tables, 39 charts and a research interview.

We show where growth can occur. Our work lets you investigate the most lucrative areas, helping you stay ahead in knowledge. 

The following sections highlight what you discover in the report. 

Our work shows you prospects for the world market and leading products

In addition to analysis of the overall world market, our study shows you revenue forecasting of five products to 2022: 
• Revlimid
• Thalomid
• Actimid
• Velcade
• Kyprolis.

Also, you see how five late-stage drug candidates - Elotuzumab, MLN9708, Perifosine, Faridak and Aplidin - can perform to 2022. See potential revenues. Our investigation shows you business research and analyses with individual sales forecasts and discussions.

Our work also breaks overall world revenue into leading countries.

National market prospects - which countries will have the highest growth?

There are many commercial opportunities in developed and developing countries, our study shows. You discover individual revenue forecasts to 2022 for eleven national markets:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC nations).

There will be high revenue growth in the established pharma markets, but also opportunities in developing countries, especially India and China. Also, product launches from 2012 onwards will benefit leading national markets. Our report shows opportunities for new drugs.

Research and development - you see trends and prospects for technologies

What about the R&D pipeline for that area of oncology? Our work shows you developmental trends by phase. You investigate developments including these:
• Monoclonal antibodies (mAbs) and other biologics
• Small-molecule products
• Protein kinase inhibition
• HDAC inhibition
• Inhibition of protein synthesis and induction of apoptosis.

Beyond proteasome inhibitors and immunomodulators, promising candidates include HDAC inhibitors, kinase inhibitors and orally-bioavailable second-generation proteasome inhibitors.

Discover how technology can change the treatment of multiple myeloma, finding progress and outlooks. Our investigation shows activities of companies treating that blood cancer.

Leading companies and revenue prospects

What will happen next? The pharmaceutical industry will improve treatments for multiple myeloma and increase revenues from 2012 to 2022. The R&D pipeline is strong.

Overall world revenue for that market area will reach $9.9bn in 2015, our report forecasts. Incidence and prevalence of multiple myeloma worldwide will stimulate demand to 2022.

Also, biological drugs will transform the market, improving treatment of blood cancer, including neoplasm in bone marrow.

In our study you find discussions and analyses of Celgene, Johnson & Johnson, Novartis, Onyx and other developers and manufacturers. This decade, many opportunities will arise for companies treating cancers.

Nine ways World Multiple Myeloma Drug Treatment Market 2012-2022 helps you

In particular, then, our report gives you the following knowledge on the topic:
• Forecasted revenue to 2022 for the overall world market - find the industry's prospects
• Potential revenues of 10 products to 2022 - analyse crucial developments
• Market forecasting to 2022 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - see leading national prospects
• Assessment of companies - find discussions of activities, products and outlooks
• Review of R&D pipelines - investigate developmental trends and progress
• Opinions on the sector - discover views, including a research interview
• Investigation of competition and opportunities influencing sales
• Discussions of what stimulates and restrains the industry and market
• Prospects for established companies and those seeking to launch products.

That work gives you quantitative and qualitative analyses with independent predictions. You receive information found only in our study. 

There you find business intelligence to help you understand the future of the industry and market. You see where prospects are lucrative and growth is likely.

Discover how our work could benefit your research and analyses, saving you time too.

By ordering now you discover prospects for products to treat multiple myeloma

Visiongain's study is for everybody needing commercial analyses for the treatment of multiple myeloma. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary
1.1 Multiple Myeloma Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods

2. Overview of Multiple Myeloma
2.1 Multiple Myeloma Represents 10-15% of All Blood Cancers 
2.2 Demographic Risk Variation in Multiple Myeloma 
2.3 Medical Basis of Multiple Myeloma: Cancer of the Plasma Cells
2.4 Diagnosing Multiple Myeloma
2.5 Stages of the Disease
2.5.1 MGUS
2.5.2 Smouldering Multiple Myeloma
2.5.3 The Durie-Salmon Staging System and the International Staging System
2.6 Treating Multiple Myeloma
2.6.1 Induction Therapy SCT Following Induction Therapy Radiotherapy: Key Treatment for Plasmacytoma The Plateau: After Induction Therapy
2.6.2 Consolidation Therapy
2.6.3 Maintenance Therapy
2.6.4 Salvage Therapy
2.6.5 Present and Future Options for Treating Multiple Myeloma: Summary

3. The Global Multiple Myeloma Market, 2012-2022
3.1 Overall Market Forecast, 2012-2022
3.2 Leading Product Classes, 2012
3.3 Leading Companies in the Market, 2012
3.3.1 Celgene Corporation: Market Leaders
3.3.2 Johnson & Johnson (Janssen): Proteosome Inhibitor and mAb Leader?
3.3.3 Novartis: The Biggest Multiple Myeloma Pipeline Novartis' Multiple Myeloma Growth Strategy
3.3.4 Bristol-Myers Squibb: Multiple Pipeline Candidates
3.3.5 Onyx Pharmaceuticals: Lead Product Cafilzomib Approved
3.3.6 Cephalon: Pioneering Oral Proteosome Inhibitors
3.3.7 Aeterna Zentaris: High Potential
3.3.8 Merck & Co. - Increasing Oncology Investment
3.3.9 Takeda: Strong Pipeline
3.3.10 Pfizer: Promising Pipeline
3.4 Leading National Markets
3.4.1 The US will Continue to Dominate the Multiple Myeloma Market
3.4.2 Japan: Revlimid Approval Driving Market Growth
3.4.3 The Leading Five EU Countries
3.4.4 BRIC Nations: Strong Projected Growth Brazil: Government Healthcare Investments Support Growth Russia: High Cancer Prevalence and Rapid Market Growth India: A Rapidly Developing Market China: Pursuing Domestic Oncology R&D

4. Leading Multiple Myeloma Treatments in 2012
4.1 Immunomodulators and Proteasome Inhibitors Dominate the Market in 2012
4.2 Revlimid (Celgene Corporation)
4.2.1 Drivers and Restraints for Revlimid, 2012
4.2.2 Market Forecast for Revlimid, 2012-2022
4.3 Thalomid (Celgene Corporation)
4.3.1Drivers and Restraints for Thalomid, 2012
4.3.2 Market Forecast for Thalomid, 2012-2022
4.4 Actimid (Celgene Corporation)
4.4.1Drivers and Restraints for Actimid, 2012
4.4.2 Market Forecast for Actimid, 2012-2022
4.5 Velcade (Johnson & Johnson, Takeda) 
4.5.1 Drivers and Restraints for Velcade, 2012
4.5.2 Market Forecast for Velcade, 2012-2022
4.6 Kyprolis (Onyx Pharmaceuticals)
4.6.1 Drivers and Restraints for Kyprolis, 2012
4.6.2 Market Forecast for Kyprolis, 2012-2022
4.7 Other Multiple Myeloma Therapy Options, 2012
4.7.1 Doxil (Johnson & Johnson)
4.7.2 Future Products

5. The Next Generation of Multiple Myeloma Treatments
5.1 Overview of the Next Wave of Myeloma Products, 2012
5.2 Elotuzumab (Abbott/ Bristol-Myers Squibb)
5.2.1 Elotuzumab: A New MAb Blockbuster?
5.2.2 Revenue Forecast for Elotuzumab, 2012-2022
5.3 MLN9708 (Millennium)
5.3.1 MLN9708: Changing the Treatment Paradigm?
5.3.2 Revenue Forecast for MLN9708, 2012-2022
5.4 Perifosine (Aeterna Zentaris)
5.4.1 Perifosine: The First of Many Protein Kinase Inhibitors?
5.4.2 Revenue Forecast for Perifosine 2012-2022
5.5 Faridak (Novartis)
5.5.1 Faridak: Leading a Wave of HDAC Inhibitors to Market?
5.5.2 Revenue Forecast for Faridak, 2012-2022
5.6 Aplidin (PharmaMar)
5.6.1 Aplidin: Inhibiting Protein Synthesis and Inducing Apoptosis 
5.6.2 Revenue Forecast for Aplidin, 2012-2022
5.7 Other Late-Stage Candidates

6. The Multiple Myeloma R&D Pipeline: Small-Molecule Products, 2012
6.1 Phase III Compounds
6.2 Phase II Compounds
6.2.1 Ridaforolimus (Ariad Pharmaceuticals, Merck)
6.2.2 Dinaciclib (Merck, Ligand Pharmaceuticals)
6.2.3 Enzastaurin (Eli Lilly)
6.2.4 GSK2110183 (GlaxoSmithKline)
6.2.5 Selumetinib (AstraZeneca)
6.2.6 Ibrutinib (Pharmacyclics)
6.2.7 Imetelstat (Geron)
6.2.8 Istodax (Celgene)
6.2.9 Givinostat (Italfarmaco)
6.2.10 Kineret (Amgen)
6.2.11 PD 0332991 (Pfizer)
6.2.12 SCIO-469 (Johnson & Johnson)
6.2.13 Dasatinib (Bristol-Myers Squibb)
6.2.14 Treanda (Cephalon)
6.3 Phase I/II Compounds
6.3.1 Torisel (Pfizer)
6.3.2 Everolimus (Novartis)
6.3.3 MLN8237 (Millennium Pharmaceuticals)
6.3.4 Nexavar (Bayer, Onyx)
6.3.5 ARRY-520 (Array BioPharma)
6.3.6 AT7519 (Astex Therapeutics)
6.3.7 Brostallicin (Pharmacia, NCI)
6.3.8 AR-42 (Arno Therapeutics)
6.3.9 KW-2478 (Kyowa)
6.3.10 Noscapine (Janssen)
6.3.11 TH-302 (Threshold Pharmaceuticals)
6.4 Phase I Compounds
6.4.1 BMS-833923 (Bristol-Myers Squibb, Exelixis)
6.4.2 Eltrombopag (GlaxoSmithKline)
6.4.3 ENMD-2076 (EntreMed)
6.4.4 Erivedge (NCI, Sidney Kimmel CCC, Genentech)
6.4.5 Folotyn (Allos Therapeutics)
6.4.6 Ganetespib (Synta Pharmaceuticals)
6.4.7 GSK2110183 (GlaxoSmithKline)
6.4.8 INK128 (Intllikine)
6.4.9 IPI-504 (Infinity Pharmaceuticals)
6.4.10 Marizomib (Nereus Pharmaceuticals)
6.4.11 Vidaza (Celgene)
6.4.12 Zarnestra (Johnson & Johnson)
6.5 Exploratory Preclinical Compounds

7. The Multiple Myeloma R&D Pipeline: Biologics, 2012
7.1 Phase III Biologic Compounds
7.2 Phase II Biologic Compounds
7.2.1 T-Cells Targeted to MAGE- A3/6 and NY-ESO-1 (Adaptimmune)
7.2.2 Siltuximab (Janssen)
7.2.3 Avastin (Roche)
7.2.4 Bexxar (GlaxoSmithKline)
7.2.5 BHQ880 (Novartis)
7.2.6 Donor Lymphocyte Infusion (MD Anderson Cancer Center)
7.2.7 Erbitux (Eli Lilly)
7.2.8 Expanded Natural Killer Cell Therapy (University of Arkansas, Celgene)
7.2.9 GVAX (Cell Genesys)
7.2.10 Hiltonol (Oncovir)
7.2.11 KLH Vaccine (National Cancer Institute)
7.2.12 Leukine (Genzyme)
7.2.13 Mapatumumab (Human Genome Sciences)
7.2.14 MDX-1097 (Immune System Therapeutics)
7.2.15 Proleukin (Prometheus Labs)
7.2.16 Rituxan (Biogen Idec, Roche)
7.2.17 Stimuvax (Merck)
7.2.18 VEGF Trap (Regeneron)
7.3 Phase I/II Compounds
7.3.1 BT062 (Biotest Pharmaceuticals)
7.3.2 HuMax-CD38 (GenMab)
7.3.3 Milatuzumab (Immunomedics)
7.3.4 MOR202 (MorphoSys)
7.3.5 SNS01-T (Senesco Technologies)
7.4 Phase I Compounds
7.4.1 ACE-041(Acceleron)
7.4.2 DFRF4539A (Genentech)
7.4.3 Lorvotuzumab Mertansine (ImmunuGen)
7.4.4 LY2127399 (Eli Lilly)
7.4.5 MFGR1877S (Genentech)
7.5.6 Reolysin (Oncolytics)
7.4.7 Dacetuzumab (Seattle Genetics)
7.5 Exploratory/Preclinical Compounds
7.6 Future Epigenetics-Based Treatments

8. Qualitative Analysis of the Multiple Myeloma Market 
8.1 Strengths: Proven Commercial Potential of the Myeloma Market
8.2 Weaknesses: A Few Products Dominate the Market
8.3 Opportunities: Cancer Treatment is a Strong Business Segment in the Pharmaceutical Industry
8.4 Threats: Will Oncology Remain a Good Investment for Pharma?
8.5 Social: Adherence, Support and Education are Key Factors
8.6 Technological: The Rise of Cancer Biology
8.7 Economic: The Cost of Cancer Treatment
8.8 Political: Broadening and Narrowing Healthcare Provision in the 21st Century

9. Research Interview
9.1 Interview with an External Authority (Views Given Anonymously)
9.1.1 Obesity is a Strong Risk Factor for Multiple Myeloma
9.1.2 Multiple Myeloma Treatment: Proactive versus Reactive
9.1.3 Treatment Options for Obese Patients
9.1.4 Multiple Myeloma Incidence Will Increase Because of Obesity

10. Conclusions
10.1 Multiple Myeloma Treatment is a Thriving Market That Will Continue to Expand from 2012 to 2022
10.2 The R&D Pipeline for Multiple Myeloma Treatment is Large and Diverse
10.3 Biological Drugs Will Transform This Market
10.4 The Industry has Commercial Challenges to Overcome
10.5 Concluding Remarks

List of Tables

Table 3.1 Global Multiple Myeloma Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 3.2 Multiple Myeloma Pipeline Candidates: Large Companies, 2012
Table 3.3 Celgene Corporation's Key Multiple Myeloma Products, 2012
Table 3.4 Johnson & Johnson's Key Multiple Myeloma Products, 2012
Table 3.5 Novartis's Key Multiple Myeloma Products, 2012
Table 3.6 Bristol-Myers Squibb's Key Multiple Myeloma Products, 2012
Table 3.7 Onyx Pharmaceutical's Key Multiple Myeloma Products, 2012
Table 3.8 Cephalon's Key Multiple Myeloma Products, 2012
Table 3.9 Aeterna Zentaris's Key Multiple Myeloma Products, 2012
Table 3.10 Merck & Co.'s Key Multiple Myeloma Products, 2012
Table 3.11 Takeda's Key Multiple Myeloma Products, 2012
Table 3.12 Pfizer's Key Multiple Myeloma Products, 2012
Table 3.13 Leading National Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 3.14 US Market: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 3.15 Japanese Market: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 3.16 EU5 National Markets: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 3.17 BRIC Markets: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.1 Leading Products in the Multiple Myeloma Market, Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.2 Revlimid Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.3 Thalomid Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.4 Actimid Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.5 Velcade Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 4.6 Kyprolis Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.1 Products in Late-Stage Development, 2012
Table 5.2 Selected Late-Stage Products in the Multiple Myeloma Market, Projected Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.3 Elotuzumab Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.4 MLN9708 Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.5 Perifosine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.6 Faridak Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 5.7 Aplidin Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2011-2022
Table 6.1 Phase III Small Molecule Compounds, 2012
Table 6.2 Phase II Small Molecule Compounds, 2012
Table 6.3 Phase I/II Small Molecule Compounds, 2012
Table 6.4 Phase I Small Molecule Compounds, 2012
Table 6.5 Exploratory/Preclinical Small Molecule Compounds, 2012
Table 7.1 Phase III Biologic Compounds, 2012
Table 7.2 Phase II Biologic Compounds, 2012
Table 7.3 Phase I/II Biologic Compounds, 2012
Table 7.4 Phase I Biologic Compounds, 2012
Table 7.5 Preclinical Biologic Compounds, 2012
Table 8.1 Strengths and Weaknesses of the Market, 2012-2022
Table 8.2 Opportunities and Threats in the Market, 2012-2022

List of Figures

Figure 2.1 Distribution of Multiple Myeloma Incidence, 2008
Figure 3.1 Global Multiple Myeloma Market Forecast: Revenues ($m), 2011-2022 
Figure 3.2 Global Multiple Myeloma Market: Established Leading Products vs Other Products, Revenues ($m), 2011-2022
Figure 3.3 Myeloma Market Breakdown by Mechanism of Action ($m), 2011
Figure 3.4 Myeloma Market Breakdown by Mechanism of Action ($m), 2022
Figure 3.5 Top Companies in the Multiple Myeloma Market: Revenues ($m), Market Share (%), 2011
Figure 3.6 Leading Regional Markets: Revenues ($m), 2011-2022
Figure 3.7 US: Multiple Myeloma Drug Market Penetration- Usage in Early Stages of Disease (%), 2011
Figure 3.8 US: Multiple Myeloma Drug Market Penetration- Usage in Later Stages of Disease (%), 2011
Figure 3.9 US Market: Revenues ($m), 2011-2022
Figure 3.10 Japanese Market: Revenues ($m), 2011-2022
Figure 3.11 EU5 Markets: Revenues ($m), 2011-2022
Figure 3.12 EU Multiple Myeloma Market: Penetration of Top 3 Drugs (%), 2011
Figure 3.13 BRIC Markets: Revenues ($m), 2011-2022
Figure 4.1 Leading Products in the Multiple Myeloma Market, Market Share (%), 2011
Figure 4.2 Leading Products in the Multiple Myeloma Market, Revenues ($m), 2011-2022
Figure 4.3 Drivers and Restraints for Revlimid, 2012
Figure 4.4 Revlimid Market Forecast: Revenues ($m), 2011-2022
Figure 4.5 Thalomid Drivers and Restraints, 2012
Figure 4.6 Thalomid Market Forecast: Revenues ($m), 2011-2022
Figure 4.7 Actimid Drivers and Restraints, 2012
Figure 4.8 Actimid Market Forecast: Revenues ($m), 2011-2022
Figure 4.9 Velcade Drivers and Restraints, 2012
Figure 4.10 Velcade Market Forecast: Revenues ($m), 2011-2022
Figure 4.11 Kyprolis Drivers and Restraints, 2012
Figure 4.12 Kyprolis Market Forecast: Revenues ($m), 2011-2022
Figure 5.1 Selected Late-Stage Products for Multiple Myeloma: Projected Revenues ($m), 2011-2022
Figure 5.2 Drivers and Restraints for Elotuzumab and Other New Myeloma MAbs, 2012
Figure 5.3 Elotuzumab Market Forecast: Revenues ($m), 2011-2022
Figure 5.4 Drivers and Restraints for MLN9708 and Other New Oral Proteasome Inhibitors, 2012
Figure 5.5 MLN9708 Market Forecast: Revenues ($m), 2011-2022
Figure 5.6 Drivers and Restraints for Perifosine and Other New Protein Kinase Inhibitors, 2012
Figure 5.7 Perifosine Market Forecast: Revenues ($m), 2011-2022
Figure 5.8 Drivers and Restraints for Faridak and Other HDAC Inhibitors, 2012
Figure 5.9 Faridak Market Forecast: Revenues ($m), 2011-2022
Figure 5.10 Drivers and Restraints for Aplidin and Other Apoptosis Inducers, 2012
Figure 5.11 Aplidin Market Forecast: Revenues ($m), 2011-2022
Figure 6.1 Distribution of Small Molecules Drugs in Development (%), 2012
Figure 7.1 Distribution of Biologic Drugs in Development (%), 2012 

 Companies Listed

AB Science
Aeterna Zentaris
Allos Therapeutics 
Ariad Pharmaceuticals
Arkansas Cancer Research Center
Arno Therapeutics
Array BioPharma
Ascenta Therapeutics
Astex Therapeutics
Ben Venue Laboratories
Biogen Idec
Biotest Pharmaceuticals
Boehringer Ingelheim
Bristol-Myers Squibb 
Broad Institute
Calistoga Pharmaceuticals
Callisto Pharmaceuticals
Cancer Research UK
Cell Genesys
Chugai Pharmaceuticals
Columbia University 
Constellation Pharmaceuticals
CytRx Corporation
Eli Lilly
European Medicines Agency (EMEA/EMA) 
Facet Biotech
Food and Drug Administration (US FDA)
Human Genome Sciences
Immune System Therapeutics 
Incyte Corporation
Infinity Pharmaceuticals
Johnson & Johnson 
Karyopharm Therapeutics
Kayaku Zentaris
Keryx Biopharmaceuticals
Kirin Pharma 
Kosan Biosciences
Kyowa Hakko Kirin
Mayo Clinic
MD Anderson Cancer Center
Merck & Co.
Millennium Pharmaceuticals 
Multiple Myeloma Research Consortium (MMRC) 
Multiple Myeloma Research Foundation 
Natco Pharma
National Cancer Institute
National Institute for Health and Clinical Excellence (NICE) 
Nereus Pharmaceuticals
Nippon Shinyaku
Novo Nordisk
Onyx Pharmaceuticals 
PDL BioPharma
Pierre Fabre
Prochon Biotech 
Prometheus Labs 
Protein Design
Rockefeller University
Seattle Genetics
Senesco Technologies 
Sidney Kimmel CCC
Sloan Kettering
Sun Pharma
Sydney Kimmel CCC
Synta Pharmaceuticals
Targa Therapeutics
Teva Pharmaceutical Industries
Threshold Pharmaceuticals 
Translational Genomics Research Institute 
University of Arkansas 
University of Illinois
Weill Cornell Medical College 
World Health Organization (WHO)
Zenyaku Kogyo 

To order this report:
Pathology Industry:
World Multiple Myeloma Drug Treatment Market 2012-2022

Contact Nicolas:
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
Certain CIOs for incomprehensible reasons keep off their cloud transformation projects several key IT disciplines including Enterprise Architecture (EA), IT Service Management (ITSM) and most importantly Project Management. Do they consider them obsolete? useless? irrelevant? ITaaS St...
Intuit uses deep-data analytics to gain a 360-degree view of its TurboTax application's users’ behavior and preferences for rapid applications improvements. The next BriefingsDirect big-data innovation case study highlights how Intuit uses deep-data analytics to gain a 360-degree view...
Here’s the thing: as sure as we’ll have another record-setting year for NFL streaming, you can also be sure that apps will fail and streaming services will go down. Whether you are dabbling in streaming or diving in whole-hog, you need to know what to do to give your users the most rel...
Carii’s platform fills the communication gap between public social apps like Facebook and Twitter and internal, private apps like Microsoft Office and team collaboration tools. Currently businesses, educational institutions and healthcare organizations cobble together their communicati...
In today’s pharmaceutical supply chain, counterfeit activity is thriving. As pharma companies have expanded target markets and outsourced production over the last decade, the supply chain has become increasingly global, virtual, and vulnerable. Illicit activity has thrived, and patient...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers